S
Consumer Staples

Steakholder Foods Ltd.

STKH
Since

Headquarters:

Israel

Exchange:

NASDAQ

Industry:

Packaged Foods

Number of Employees:

43.00

Current Fiscal Year:

2024

Market Cap:

8.65M

Price per Share:

$3

Quarterly Dividend per Share:

Year-to-date Performance:
-64.2857%
Dividend Yield:
%
Price-to-book Ratio:
1.47
Trailing P/E Ratio:
N/A

Price History

Latest Prices

DateOpenHighLowClose
2025-05-012.993.052.813
2025-04-303.023.09912.9063
2025-04-292.943.222.93
2025-04-283.63.63832.763.22
2025-04-253.753.753.0153.55

Steakholder Foods Ltd., a deep-tech food company, develops cultivated meat production technologies in Israel. The company develops alternative protein manufacturing machines, including three-dimensional printers to produce meat, fish, and seafood analogs; and hybrid cultivated meat technologies to be integrated into production processes, as well as hybrid meat blends, cell lines, growth media, and bioreactors. It also offers premix blends as a plant-based alternative for meat and seafood under the SHMeat and SHFish brand names. In addition, the company provides consulting and implementation services. It serves food processing and retail companies; and cultivated meat producers. Steakholder Foods Ltd. was founded in 2019 and is headquartered in Rehovot, Israel.

Financial Performance

2024 Revenue:0.00

Detailed view of quarterly revenue

2024 Net Income:-21.61M

Detailed view of quarterly net income

2024 Free Cash Flow:-7.45M

Overview of free cash flow for the quarter

Annual Revenue Comparison

Compares total annual revenues

Similar Companies

Health Care
P
Pluri Inc.
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and cell-based technologies for various industries. It develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and a novel immunotherapy platform. The company's product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to COVID-19, peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, is composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and phase I trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform. It also offers cell manufacturing services; cell-based coffee; and develops and commercializes cultivated meat products. The company operates in the field of regenerative medicine, food-tech, CDMO, and agtech. It has collaboration agreement with Bar-Ilan University to advance cancer immunotherapy for solid tumors. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
26.51M
Market Cap
*Data based on the last 12 months.